Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-22-003407

← back to feed
Filed
Feb 8, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2022 · Feb 4, 2022 60.02M sh
Current Liabilities Q2 2022 · Dec 31, 2021 $65.37K
Current Liabilities Q2 2022 · Jun 30, 2021 $39.32K
Current Assets Q2 2022 · Dec 31, 2021 $2.94K
Current Assets Q2 2022 · Jun 30, 2021 $25.54K
Total Assets Q2 2022 · Dec 31, 2021 $2.94K
Total Assets Q2 2022 · Jun 30, 2021 $25.54K
Operating Cash Flow Q2 2022 · Dec 31, 2020 −$40.65K
Stockholders Equity restated Q2 2022 · Dec 31, 2020 $23.56K
Stockholders Equity Q2 2022 · Jun 30, 2020 −$6.37K
Sga Expense Q2 2022 · Dec 31, 2020 $818.8K
Sga Expense Q2 2022 · Dec 31, 2020 $1.86M
Net Income Q2 2022 · Dec 31, 2020 −$828.03K
Net Income Q2 2022 · Dec 31, 2020 −$1.89M